The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent adverse events occurred in 80% and 81% of dazukibart 150 mg and 160 mg groups.

Received FDA orphan drug designation for the treatment of dermatomyositis in April 2017. Received FDA approval for the treatment of dermatomyositis in adults in July 2021. The mechanism of action ...

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...

Achievement of cancer remission was associated with dermatomyositis complete clinical response among patients with cancer-associated DM.

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.

Dermatomyositis: Causes skin rashes and muscle ... Some cutting-edge regenerative treatments, which have been successfully introduced in Bangladesh, include: 1. Prolotherapy: A treatment that ...

An autoimmune disease crippled his lungs. Hooked up to a machine that oxygenated his blood for him, for 18 months the boy ...

NHSO approves six new drugs for insurance, enhancing treatments for tuberculosis, hepatitis C, and lymphoma, saving millions ...

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

and Rare Pediatric Disease Designation for the treatment of juvenile dermatomyositis. Any statements in this press release about the future expectations, plans and prospects of the Company, including ...